Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRANDA phase 3 trial of tozorakimab in symptomatic COPD with prior exacerbations
CTR20240891Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Apr 2024; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20240891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240891.